VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study

Interim Phase III data showed povetacicept cut proteinuria by 52% in IgA nephropathy, driving a jump in Vertex shares. The strong Phase III signal raises prospects for an accelerated FDA approval pathway, materially improving the program's regulatory and commercial outlook and likely re-rating the stock.

Analysis

Interim Phase III data showed povetacicept cut proteinuria by 52% in IgA nephropathy, driving a jump in Vertex shares. The strong Phase III signal raises prospects for an accelerated FDA approval pathway, materially improving the program's regulatory and commercial outlook and likely re-rating the stock.